A61K 40/4245
Tyrosinase or tyrosinase related proteinases [trp-1 or trp-2]
Official title: {Tyrosinase or tyrosinase related proteinases [TRP-1 or TRP-2]}
A61K40/4245 (Tyrosinase or tyrosinase related proteinases [trp-1 or trp-2]) appears on 65 US grants and 126 published applications in this corpus.
Search patents in A61K- Granted patents
- 65
- Published applications
- 126
- Assignees
- 80
- Inventors
- 235
- Latest grant
- 4 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1996 | 1 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 1 | 0 |
| 2001 | 1 | 0 |
| 2002 | 1 | 4 |
| 2003 | 1 | 1 |
| 2004 | 1 | 7 |
| 2005 | 0 | 0 |
| 2006 | 2 | 3 |
| 2007 | 1 | 3 |
| 2008 | 2 | 7 |
| 2009 | 2 | 4 |
| 2010 | 1 | 6 |
| 2011 | 3 | 2 |
| 2012 | 2 | 5 |
| 2013 | 5 | 6 |
| 2014 | 3 | 5 |
| 2015 | 2 | 4 |
| 2016 | 4 | 0 |
| 2017 | 3 | 7 |
| 2018 | 3 | 6 |
| 2019 | 1 | 8 |
| 2020 | 2 | 8 |
| 2021 | 4 | 6 |
| 2022 | 2 | 9 |
| 2023 | 5 | 8 |
| 2024 | 6 | 12 |
| 2025 | 3 | 3 |
| 2026 | 3 | 2 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Compositions and methods regarding engineered and non-engineered γδ T-cells for treatment of solid tumors4 Aug 2026US 12,698,340 B2Adicet Therapeutics, Inc.
- Methods and compositions for treating cancer24 Mar 2026US 12,582,626 B2The Wister Institute of Anatomy and Biology
- T cell receptors and methods of use thereof17 Mar 2026US 12,577,287 B2University Health Network
- Compositions and methods for treating cancer6 May 2025US 12,291,559 B2Regeneron Pharmaceuticals, Inc.
- Synthetic immune receptors and methods of use thereof8 Apr 2025US 12,269,859 B2Angeles Therapeutics, Inc.
- Polynucleotides, polypeptides, cells, and compositions comprising synthetic immune receptors with methods of manufacture and treatment18 Jun 2026US 2026/0167693 A1Angeles Therapeutics, Inc.
- In Vivo Genetic Engineering of Antigen Responsive Cells5 Mar 2026US 2026/0062684 A1Thomas Jefferson University
- Compositions and methods for treating cancer10 Jul 2025US 2025/0223334 A1Regeneron Pharmaceuticals, Inc.
- T cell expressing an fc gamma receptor and methods of use thereof22 May 2025US 2025/0163128 A1Ramot at Tel-Aviv University Ltd.
- Antigen-binding proteins targeting melanoma differentiation antigens and uses thereof23 Jan 2025US 2025/0026855 A1Memorial Sloan Kettering Cancer Center
Most cited
By later US patents
- High affinity T cell receptor and use thereof66US 8,697,854 B2Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) · 2014
- PD-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof58US 8,287,856 B2BioSante Pharmaceuticals, Inc. · 2012
- Stat3 antagonists and their use as vaccines against cancer41US 7,638,122 B2The Johns Hopkins University · 2009
- PS-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof41US 8,580,247 B2Aduro Gvax Inc. · 2013
- Method of treating cancer cells to create a modified cancer cell that provokes an immunogenic response33US 7,361,360 B2Lipid Sciences, Inc. · 2008